Loading
A phase 1/2 trial of Petosemtamab, Pembrolizumab, FOLFIRI in colorectal cancer and head and neck squamous cell carcinoma, run by Merus B.V., now recruiting.
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03526835 by Merus B.V., with 560 participants planned, started 2018-05-02 and due to reach its primary completion in 2028-05. Interventions recorded: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX. Conditions listed: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer. No results are recorded here; the registry entry is the source.
Shares Petosemtamab, Genmab, FOLFIRI (5-FU, leucovorin, irinotecan), Bispecific antibodies.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Genmab, Bispecific antibodies, Colorectal cancer.
Shares Petosemtamab, Head and neck squamous cell carcinoma, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Pembrolizumab, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Pembrolizumab, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Colorectal cancer.